🇺🇸 FDA
Pipeline program

Selinexor

IST-321

Phase 1 small_molecule active

Quick answer

Selinexor for Refractory Multiple Myeloma is a Phase 1 program (small_molecule) at Karyopharm Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Karyopharm Therapeutics
Indication
Refractory Multiple Myeloma
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials